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Abstract
Across the spectrum of industrial sectors, including pharmaceuticals, chemicals, personal care products, food additives
and their associated regulatory agencies, there is a need to develop robust and reliable methods to reduce or replace
animal testing. It is generally recognised that no single alternative method will be able to provide a one-to-one replacement
for assays based on more complex toxicological endpoints. Hence, information from a combination of techniques is
required. A greater understanding of the time and concentration-dependent mechanisms, underlying the interactions
between chemicals and biological systems, and the sequence of events that can lead to apical effects, will help to move
forward the science of reducing and replacing animal experiments. In silico modelling, in vitro assays, high-throughput
screening, organ-on-a-chip technology, omics and mathematical biology, can provide complementary information to
develop a complete picture of the potential response of an organism to a chemical stressor. Adverse outcome pathways
(AOPs) and systems biology frameworks enable relevant information from diverse sources to be logically integrated.
While individual researchers do not need to be experts across all disciplines, it is useful to have a fundamental under-
standing of what other areas of science have to offer, and how knowledge can be integrated with other disciplines. The
purpose of this review is to provide those who are unfamiliar with predictive in silico tools, with a fundamental under-
standing of the underlying theory. Current applications, software, barriers to acceptance, new developments and the use
of integrated approaches are all discussed, with additional resources being signposted for each of the topics.
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Introduction
The agenda for change has been clearly mandated, with a
global drive towards reducing, refining or replacing animal
tests with non-animal alternatives. Legislative changes, as
well as commercial and ethical pressures, have provided
motivation for the pursuit of alternatives to the traditional
in vivo assays used in product development and safety
assessment. However, tangible progress varies signifi-
cantly between sectors and geographic regions.1 For exam-
ple, cosmetic products or their ingredients, to be marketed
within the European Union (EU), can no longer be tested on
animals, whereas the registration of new therapeutic enti-
ties (NTEs) is contingent upon safety, efficacy and dosing
protocols being established in animal models.
In order to develop products that are safe for humans and
animals (including environmental species) there is a need
to understand the potential effects of chemicals, on a wide
range of organisms, and how this can be affected by factors
such as developmental stage, health status or individual
genetic composition. The ability of a chemical to elicit an
effect is determined by its concentration–time profile
(internal exposure) at a relevant site, as well as its inherent
activity (toxicity). For some chemicals, data may be avail-
able for certain species, under specific exposure scenarios.
However, there are no chemicals for which comprehensive
data are available for all target and non-target species that
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Table 1. A summary of the abbreviations and key terminology used within this review.
Abbreviation
or key term Definition
ADME Absorption, distribution, metabolism and excretion
ANN Artificial neural network; used to model non-linear relationships between molecular properties and endpoints
of interest by mimicking learning processes in the brain
ANTARES Alternative Non-Testing Methods Assessed for REACH Substances (project)
AOP Adverse Outcome Pathway; the sequence of events resulting from a perturbation of a biological system,
beginning with a molecular initiating event and ending with a potentially adverse response
AOP-KB Adverse Outcome Pathway-Knowledge Base; a repository for AOPs and associated information
APCRA Accelerating the Pace of Chemical Risk Assessment
AUC Area Under concentration–time Curve
CAS Chemical Abstracts Service
Category formation/
grouping
Placing chemicals into rationally defined categories/groups on the basis of a shared property or chemical
similarity
CEFIC-LRI European Chemical Industry Council’s Long Range Initiative
ChEMBL Database of bioactive molecules, curated and maintained by EMBL
CRED Criteria for reporting and evaluating ecotoxicity data
DA Defined approach; using a fixed data interpretation procedure from defined sources to assist decision making
DIP Data interpretation procedure
Discriminant analysis Determining a function (for example cut-off values, a line or plane) that differentiates chemicals belonging to two
or more different classes
DNN Deep learning neural networks; an adaption of ANNs wherein multiple endpoints are considered
simultaneously
EC50 Half maximal effective concentration for a drug or toxicant
ECHA European Chemicals Agency
EFSA European Food Safety Authority
EHOMO/ELUMO Energy of the highest occupied molecular orbital/energy of the lowest unoccupied molecular orbital; indicators
of molecular reactivity
EINECS European inventory of existing commercial chemical substances
EMBL European Molecular Biology Laboratory
EPA Environmental Protection Agency
Exposome The total exposure of an organism (e.g. to a chemical) over the course of their lifetime in relation to health
GHS Global harmonised system
HIA Human intestinal absorption
HTS High-throughput screening
IATA/ITS Integrated approaches to testing and assessment/integrated testing strategies; methods to rationally combine
information from different sources to inform decision making in safety assessment
ICCR International Cooperation on Cosmetics Regulation
ICCVAM Interagency Coordinating Committee on the Validation of Alternative Methods
ICH International Council for Harmonisation of technical requirements for pharmaceuticals for human use
InChI International chemical identifier
JRC Joint Research Centre
KE Key Event; a key step within an AOP, for example, a (measurable) change in biological state
KER Key Event Relationship; the connection between KEs in an AOP
Kp Skin permeability coefficient
k-NN k-Nearest Neighbours; a method to identify chemicals that are similar (with respect to a given property) that
may be used, for example, to assign chemicals to classes
LD50 Lethal dose for 50% of test organisms
(continued)
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Table 1. (continued)
Abbreviation
or key term Definition
LLNA Local lymph node assay; used to assess skin sensitisation potential
Log P Logarithm of the octanol: water partition coefficient; an indicator of relative lipophilicity/hydrophilicity
Mathematical biology The application of mathematical approaches to describe or solve issues in biology
MIE Molecular initiating event; the first step in an adverse outcome pathway involving the initial interaction between
a chemical and a biological macromolecule
NAMs New approach methodologies; non-animal alternatives to testing
NIH National Institutes of Health
NTE New therapeutic entities
OECD Organisation for Economic Co-operation and Development
PBK model Physiologically-based kinetic model; describes the concentration–time profile of a chemical within the body,
considering the relevant organs of the body as compartments connected by the vascular system
PBPK/PBTK model Physiologically-based pharmacokinetic/physiologically-based toxicokinetic model; PBK models referring
explicitly to chemicals with pharmacological/toxicological activity
PK Pharmacokinetics; study of the concentration–time profile of chemicals (specifically pharmaceuticals) within an
organism
qAOP Quantitative AOP; a quantitative model for an AOP usually based on data for KEs and KERs
QIVIVE Quantitative in vitro to in vivo extrapolation; used to correlate exposure in vivo with the dose at which an effect
was observed in vitro
QMRF QSAR model reporting format
QSAR Quantitative structure–activity relationship; a mathematical relationship between the activity of a chemical and
its structural and/or physico-chemical properties
QSP Quantitative systems pharmacology; used in drug discovery to model disease pathology, intervention and
response
QST Quantitative systems toxicology; used to investigate the response of a system to a toxicant with potential to
integrate concentration–time and effect models
QSPR Quantitative structure–property relationship; a mathematical relationship between a property of a chemical and
its structural feature
RA Read-across; using information from chemical(s) with known properties to infer information for other similar
chemical(s) where data are lacking
RAAF Read-across assessment framework; guidance from ECHA on the evaluation process for RA in regulatory
submissions
REACH Registration, evaluation, authorisation and restriction of chemicals
SA Structural alert; a molecular feature known to be associated with a specific activity (toxicity)
SAAOP Society for the Advancement of Adverse Outcome Pathways
SAR Structure–activity relationship; a qualitative relationship betweena molecular feature of a chemical and its activity (or
property of interest)
SCCS Scientific Committee on Consumer Safety
SciRAP Science in risk assessment and policy (project)
SMILES Simplified molecular input line entry system
SVM Support vector machine; a machine learning algorithm that can be used to place data into classes
Systems biology A holistic approach to determining how an organism responds to stimuli, considering the multiple interacting
components of the system
TEST Toxicity estimation software tool from the US EPA
TTC Threshold of toxicological concern; a level of exposure to a chemical below which there is assumed to be no
appreciable risk to human health
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might be exposed to it. Considering the totality of the expo-
some — ranging from once in a lifetime, to multiple daily
exposure (orally, dermally, via inhalation, etc.) of low or
high concentrations of a myriad of chemicals and mixtures
— chemical safety assessment clearly cannot be achieved
through testing alone, and thus predictive methods are
essential. As a one-to-one replacement of an animal test
with a non-animal alternative is not generally practicable,
due to the inherent complexity of biological systems, it is
necessary to employ a range of alternative methods. Each
method can contribute a different piece of information that
can be used to build a complete, mechanistic understanding
of how a chemical interacts with a biological system, to
cause a perturbation resulting in an apical effect (i.e. an
observable or measurable whole-organism outcome). In
silico (computational), in vitro, omics, organ-on-a-chip
technology, high-throughput screening (HTS) and mathe-
matical biology can all play a role in providing comple-
mentary information.2
Knowledge of the key terminology used in this area of
science is important to understanding this review, hence
commonly used abbreviations and key terms that are used
herein have been summarised in Table 1. For example, the
term ‘new approach methodology’ (NAM) applies to any of
the non-animal alternatives that can be used alone or in
combination to provide information for safety assessment.
‘Integrated approaches to testing and assessment’ (IATAs)
combine information from a range of sources to determine
if there is sufficient knowledge on which to make safety-
based decisions, or direct future experiments to fill knowl-
edge gaps. ‘Defined approaches’ (DAs) use a fixed data
interpretation procedure (DIP) to interpret information
from a defined set of sources to assist decision making.3
It is the combination of data on absorption, distribution,
metabolism and excretion (ADME), as well as activity
(hazard or toxicity) data that leads to a more realistic pre-
diction of the potential of a chemical to elicit an effect in
vivo. A wide range of in silico tools are available that can
predict the ADME characteristics of a chemical (determi-
nants of its internal exposure) as well as its intrinsic activity
(toxicity). While external exposure is an essential precursor
to this process, the mathematical models to predict external
dose for different products, pollutants and scenarios are
beyond the scope of the current article (the reader is
referred to previous reviews of exposure modelling
software).4,5
• In silico tools use exisng data or informaon derived from molecular structure to make predicons regarding absorpon,
distribuon, metabolism and excreon (ADME properes that determine internal exposure) and / or biological acvity
(toxicity or hazard) of a chemical.
• Methods range from simple (quantave) structure-acvity (property) relaonships to more complex models.
• Integrang informaon from different sources enables more accurate predicons of chemical acvity used in product
development and safety assessment
Acvity / Hazard Idenficaon ADME (Internal Exposure)
Molecular features
Whole molecule properes; 
stascal analysis
Advanced models / 
plaorms
Integrang strategies
Product development and safety assessment
Read-across; integrated approaches to tesng and assessment; 
defined approaches; quantave systems biology 









(Quantave) adverse outcome 
pathways ((q)AOPs)
Structure-acvity relaonships (SARs);  
structural alerts
Figure 1. Key Concepts Box: Overview of in silico tools and their applications.
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The power of in silico models is that the predictions are
derived entirely from the structures of the chemicals of
interest. The fundamental tenet of these models is that the
intrinsic properties, potential interactions and ultimate
effects of a chemical are encoded within its molecular
structure; understanding this enables (quantitative) struc-
ture–activity relationship ((Q)SAR) or (quantitative) struc-
ture–property relationship ((Q)SPR) models to be
developed. Similar chemicals are expected to elicit similar
effects. Hence, knowledge of one chemical (or a group of
chemicals) can be used to predict the characteristics of
similar chemicals. Limitations to this approach are recog-
nised, for example, the level of sophistication by which the
molecule can be described at a structural level and the role
of mitigating factors (e.g. structural features that may
attenuate or intensify a response) can alter activity. The
‘similarity-paradox’ refers to the problem of chemicals that
are ostensibly similar, but exhibit markedly different activ-
ity profiles. Activity cliffs occur when a smooth relation-
ship between structure and activity abruptly ceases, and a
small change in structure leads to an extreme change in
biological response. Activity cliffs may provide an oppor-
tunity for medicinal chemists to develop new leads, but
they are problematic in developing QSARs.6
Notwithstanding, in silico models have been used for a
multitude of applications, from predicting the toxicity of
pollutants or agrochemicals to environmental species, to
optimising drug candidates. The history of the development
of in silico tools has been summarised recently.7 Thousands
of models and hundreds of software packages for predicting
ADME properties and biological activity are now avail-
able. The purpose of this review is neither to recount the
complete history of the field, nor to catalogue large num-
bers of available models or software applications. Rather,
its purpose is to provide an introduction to the breadth of
tools available, as well as the underlying theory and appli-
cations of these tools, for those new to the area of in silico
prediction. The range of techniques and their applications
— for example, prediction of intrinsic activity (hazard) or
internal exposure (ADME properties) — are summarised as
key concepts in Figure 1 and explained in detail below.
Examples are also given regarding the use of these tools
across different sectors, e.g. drug development in the phar-
maceutical industry, safety assessment in the personal care
product and food industries, and environmental toxicity
prediction. An explanation of the theories that underpin the
key methods, and how model reliability may be evaluated
is also presented, with additional resources (e.g. exemplar
software and comprehensive reviews of individual meth-
ods) being signposted within the relevant sections.
Applications of in silico models
As the number of in silico tools has expanded, so too has
their application across different industrial and regulatory
sectors. This is advantageous, as new information on the
development or application of tools in one sector can be
leveraged by another. This cross-disciplinary sharing of
ideas and practice enables more rapid advancement, accep-
tance and uptake of new in silico methods. Historically, in
silico models have been widely used for predicting the
toxicity of chemicals to environmental species, particularly
fish, aquatic invertebrates, algae and more recently bees.8
However, there are multiple examples of their application
within medicinal chemistry, in the design of bioactive che-
micals, predictive toxicology and safety assessment.9 In the
pharmaceutical industry, models have been used extensively
to maximise the efficiency of the drug development process,
to ensure that only those candidates likely to be successful
are taken forward to the animal testing stages and to avoid
late-stage attrition or post-marketing withdrawal. The per-
sonal care product, (agro)chemical and food industries also
use a range of in silico tools in product development, and as
a result there is now increased recognition of the potential of
in silico tools to provide information for regulatory submis-
sions to meet legislative demands.
The EU regulation concerning the Registration, Evalua-
tion, Authorisation and restriction of Chemicals (REACH),
which came into force in June 2007, aims to protect humans
and the environment from the adverse effects of the use of
chemicals.10 The REACH regulation specifically promotes
the use of in silico prediction (e.g. QSAR and read-across
methods) as alternatives to animal testing, providing that:
the results are derived from a (Q)SAR model for which
scientific validity has been established; the substance falls
within the applicability domain of the (Q)SAR model; the
results are adequate for purpose (e.g. classification or label-
ling); and adequate and reliable documentation of the
applied method is provided. ECHA’s 4th Report on the Use
of Alternatives to Testing on Animals for the REACH Reg-
ulation confirms that results from alternative methods con-
tinue to be used over and above new animal tests in dossiers
submitted for REACH.11 Read-across is the most common
alternative strategy, but use is also made of QSARs, waiv-
ing and integrated testing strategies (ITS).
Since 2013, the Cosmetics Regulation (Regulation (EC)
No 1223/2009) has banned the testing of cosmetic ingredi-
ents and products on animals, and has prohibited the mar-
keting of cosmetics for which the ingredients or products
were tested on animals since the introduction of the ban.12
The 10th revision of the Notes of Guidance for the testing
of cosmetic ingredients and their safety evaluation (from
the European Commission’s Scientific Committee on
Consumer Safety (SCCS)) similarly promotes the use of
in silico models, stipulating that for safety evaluation of
cosmetic ingredients, all available scientific data are con-
sidered, including results from (Q)SARs, chemical cate-
gories, grouping, read-across and physiologically-based
kinetic (PBK) modelling.13 For the safety assessment of
food and food ingredients, a stepwise roadmap for
Madden et al. 5
evaluation that draws upon information from in silico
models including QSAR and read-across has been
proposed.14
In the USA, the Frank R Lautenberg Chemical Safety
for the 21st Century Act of Congress (2016) enshrines into
US law that animal studies should be reduced or replaced as
much as practicable.15 A cross-sector partners’ forum
(organised by the European Partnership for Alternatives
to Animal Testing (EPAA)) resulted in a report on the use
of read-across by the pharmaceutical, cosmetics (personal
care product), chemical, agrochemical, food and fragrance
industries and their associated regulatory organisations.
The report identified cross-industry synergies in
approaches, and highlighted the need to incorporate toxi-
cokinetic information in read-across.16 This evidences the
increasing use of in silico tools across all sectors, highlight-
ing the extensive economic and ethical contribution of this
area of science.
Databases
The rate of acquisition of scientific knowledge is expand-
ing more rapidly now, than at any other time. To maximise
the value of this new information, there is a significant
need for much of it to be made available in the public
domain. This has led to a rapid expansion of databases,
often freely accessible, that can provide a wealth of infor-
mation on millions of chemicals. Whether or not a data-
base itself can strictly be defined as an in silico tool is
debatable. However, the searching strategies incorporated
within modern databases (e.g. algorithms to identify sim-
ilar chemicals or the capacity to modify and combine
search parameters) are certainly some of the most widely
used ‘tools’ in finding data on chemicals to develop and/or
evaluate models. Often chemicals are characterised as
being ‘data-rich’ (having a high volume of relevant data
readily available) or ‘data-poor’ (having little or no rele-
vant data available).
Table 2. Summary information for key, freely available databases for toxicological, physico-chemical and other relevant information for
safety assessment.
Database Website details and further information
AMBIT http://cefic-lri.org/toolbox/ambit/
Developed by European Chemical Industry Council’s Long Range Initiative (Cefic-LRI), it contains information on
>450,000 chemicals including the European Chemicals Agency’s (ECHA’s) REACH data.
Chemspider http://www.chemspider.com/
Developed by the Royal Society of Chemistry, it provides information on over 83 million chemicals, using 275
data sources; includes direct links to other relevant resources.
ChemIDplus https://chem.nlm.nih.gov/chemidplus/
Developed by the US National Library of Medicine; contains information relating to >300,000 chemical structures





Hosted by the US Environmental Protection Agency (US EPA); a repository of data currently for 875,000
chemicals; links out to additional data sources; integrates data e.g. from ToxCast/Tox21 high-throughput
screening initiatives.
eChemPortal http://www.echemportal.org
Developed in collaboration with the Organisation for Economic Cooperation and Development (OECD),
provides links to information prepared for governmental chemical reviews at national and international




European Molecular Biology Laboratory’s European Bioinformatics Institute (EMBL-EBI); source of biological
and biomolecular data incorporating the ChEMBL database of bioactive molecules with drug-like properties
(>15 million values from >1.8 million chemicals).
OCHEM https://ochem.eu/home/show.do
Online chemistry database with modelling environment; 2.9 million records for over 600 properties, based on the
wiki principle.
QSAR Toolbox https://www.qsartoolbox.org/
Developed to help fill data gaps in (eco)toxicity data; version 4.4 contains 57 databases, with 2.6 million data
points for 92,134 chemicals.
PubChem https://pubchem.ncbi.nlm.nih.gov/
Open chemistry database from US National Institutes of Health (NIH) with data on over 102 million chemicals.
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The interrogation of existing databases is a vital first
step in determining potential effects of a chemical; if
appropriate data are already available, then this obviates
the need for testing or generating predictions. Generally,
it is better to use an experimental rather than predicted
value (unless there are known problems with the experi-
ment); where multiple values are available, judgement, or
consideration of data quality must be applied, as discussed
in the next section. If information is not available for the
chemical of interest, it may be possible to make a predic-
tion through rational use of information available for other
chemicals; this practice underpins in silico modelling tools
such as (Q)SAR and read-across. Identifying the existing
data also highlights where there are knowledge gaps, and
therefore can help to prioritise future testing strategies,
ensuring that the maximum information is obtained from
those chemicals that are selected for testing.
Databases are usually searchable by using a range of
chemical identifiers, such as:
– name;
– Simplified Molecular Input Line Entry System
(SMILES) string;
– hashed code derived from the International Chemi-
cal Identifier (i.e. InChIKey); or
– registry number (e.g. Chemical Abstracts Service
(CAS) or European INventory of Existing Commer-
cial chemical Substances (EINECS) number).
Of paramount importance is ensuring that the data obtained
(activity, toxicity, hazard data or ADME values) have been
correctly and unambiguously assigned to the correct chem-
ical structure. With increasing automation, it is easy for
errors in chemical names or structures to be propagated
in databases or literature collations. High quality databases
often report the methods used to assess data record accu-
racy and may have standard protocols for error reporting
and fixing. Cross-checking that at least two, and ideally
three, identifiers give consistent results can be performed
to check consistency in structure identification; where
inconsistencies are identified, primary literature may need
to be consulted. Some databases offer the capability to
search for chemicals that are similar to the chemical of
interest by using chemical fingerprints (vide infra) and/or
physico-chemical properties.
In a recent comprehensive review, over 900 databases
were identified and characterised in terms of the type of
information available, as well as their public or commercial
accessibility, interoperability, search criteria, etc.17 The
categories for the types of database considered (with the
number of associated databases given in parentheses) were:
biological (268); drug discovery (157); clinical trials (116);
chemistry (80); omics (60); toxicology (57); protein–pro-
tein interactions (54); alternative methods (39); ADME
(38); pathways (38); environmental exposure (30);
nanomaterials toxicity (22); and patents (9). Of the hun-
dreds of databases available, some representative examples
of freely accessible databases are shown in Table 2, in order
to indicate the nature and scope of these resources.
PubChem is one of the most comprehensive sources of
chemical information. It can be searched by using name,
synonyms, molecular formula, structure, SMILES, InChI-
Key or registry number. It is also possible to search for
chemicals that are similar with respect to 2-D fingerprint
or physico-chemical properties. The type of information
available is divided into approximately 20 major categories
(depending on the nature of the chemical), and each major
category expands into multiple subcategories providing
information on, for example: identifiers; chemical and
physical properties; uses; pharmacology; safety/hazard
data; and toxicity data references. Similarly, Chemspider
is another comprehensive resource with information on
identifiers, physical properties and chemical properties
(experimental and/or predicted values), with links to pre-
dictions from ACD/labs, EPISuite, Chemaxon and Mcule.
Chemspider provides information on common uses, chem-
ical class, safety information, references, and links to other
sources of information.
ChemIDplus is searchable by using a range of identi-
fiers, and provides chemical classification codes, physical
property and toxicity data (e.g. LD50 data for multiple spe-
cies and routes) with links to original references.
The Computational Toxicology (CompTox) Chemicals
Dashboard can be searched by chemical identifiers (e.g.
CAS number), product categories and assays/genes associ-
ated with high-throughput screening. It provides extensive
information on chemistry, toxicity and exposure data,
including physical and chemical properties, environmental
fate, usage, in vivo toxicity data and results from a wide
range of in vitro assays.
The QSAR Toolbox has been developed to support read-
across predictions. A significant number of databases have
been donated to this project, hence, it represents a useful
resource for human and environmental toxicity endpoint
data, as well as physico-chemical property and metabolic
data.
AMBIT, also designed to support chemical safety
assessment, contains the REACH data from the European
Chemicals Agency, as well as the European Food Safety
Authority (EFSA) OpenFoodTox databases.
The eChemPortal is searchable by chemical name, reg-
istry number, chemical property or Global Harmonised
System (GHS) classification. It provides links to hazard
and risk information prepared for chemical review, includ-
ing data on exposure and use.
The online chemical database with modelling environ-
ment (OCHEM), contains information on physical and
chemical properties, ADME, biological activity and toxi-
city data from both publications and user uploads.
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Finally, the European Molecular Biology Laboratory
(EMBL) describes itself as a source of the “world’s most
comprehensive range of freely available and up-to-date
molecular data resources.” ChEMBL (which is developed
and maintained by EMBL) provides extensive datasets of
binding, ADME and biological activity data.
Data quality assessment
The scale of the resources outlined in Table 2 indicates the
vast amount of data that are available, from which in silico
models can be built to predict properties of interest (e.g.
ADME or activity/toxicity). It is essential to ascertain the
quality of the data to be used, as any model is only as good
as the data on which it is built. Equally important, is the
sequitur that no model can be more accurate than the data
from which it is derived. In addition, biological data are
inherently variable, and this sets the upper limit for the
accuracy of predictive models, as was recently exemplified
in an investigation into the levels of uncertainty in models
based on data from the US EPA’s Toxicity Reference Data-
base (https://www.epa.gov/chemical-research/exploring-
toxcast-data-downloadable-data).18
‘Quality’ is a relative term — the purpose for which the
data are to be used dictates the minimum level of data
reliability and relevance that would be considered accep-
table, i.e. this determines the suitability of the data for a
given purpose (data adequacy). Definitions for the various
terms that are associated with data quality have been out-
lined previously,19 but they are summarised below:
– Validity of data can be defined as “evaluating the
method used to generate data relative to accepted
guidelines” or “the extent to which the methods used
find the truth as a result of the investigator actually
measuring what they intended to measure.”
– Accuracy can be defined as “the closeness of agree-
ment between test method results and accepted ref-
erence values.”
– Reliability of data is linked to the reliability of the
experiments carried out. For example, whether the
results can be confirmed by comparison to stan-
dards, and whether the methodology is repeatable.
– Relevance is the relationship between the test that is
carried out and the effect that is of interest (i.e. the
meaningfulness of the assay). For example, the high-
est quality data are required for the safety assess-
ment of individual chemicals; however, lower
quality data may suffice for general screening or
ranking of chemicals in product development.
Industry often works with specific types or subsets of che-
micals; therefore, models built using in-house data can be
more relevant than those built using external data sets. In-
house data sources are usually reliable and have the
advantage of an audit trail for tracing or resolving issues
where necessary. One disadvantage in attempting to for-
mally assess the quality of data is that the results can be
highly subjective. The Klimisch criteria are the most
widely used for classifying data quality.20 The application
of these criteria enables data to be categorised as: (i) reli-
able without restriction; (ii) reliable with restriction; (iii)
unreliable; or (iv) not assignable (i.e. insufficient informa-
tion exists on the data for a judgement of its quality to be
made). The ToxRTool available from the European Com-
mission’s Joint Research Centre (JRC) (https://eurl-ecvam.
jrc.ec.europa.eu/about-ecvam/archive-publications/toxr
tool) is designed to help data users and modellers assign
Klimisch quality scores to in vitro and in vivo toxicity data,
by posing a series of questions relating to the methodological
details. More recently, the Science in Risk Assessment and
Policy (SciRAP) project has developed web-based tools
(www.scirap.org) for the evaluation and reporting of
(eco)toxicity data with the aim of increasing the structure
and transparency of data reliability assessments. The Criteria
for Reporting and Evaluating ecotoxicity Data (CRED) pro-
vide a means to characterise the quality of data for eco-
toxicological endpoints.21 The quality of the data used to
build or evaluate a (Q)SAR model is a determinant of
model quality and prediction reliability. Hence, appropriate
precautions should be taken, such as checking for accuracy
(e.g. avoidance of transcription errors in large compilations),




Structure–activity relationships (SARs) refer to any defin-
able relationship between a molecular feature of a chemical
and its activity. Simple ‘rule-based’ classification schemes,
cut-off criteria or generic rules-of-thumb are the simplest
examples. Lipinski’s Rule of Fives, which is designed to
screen out drug candidates with potentially poor oral
absorption, is probably the most well-known of these.22
Lipinski’s Rule states that chemicals with a molecular
weight above 500 Da, a logarithm of the octanol:water
partition coefficient (log P) above 5, more than 5 hydrogen
bond donors or more than 10 hydrogen bond acceptors, are
associated with low oral absorption. Simple rules have also
been developed for other properties of interest — for exam-
ple, if the number of nitrogen plus oxygen atoms in a
molecule is less than or equal to five, it has the potential
to penetrate the blood–brain barrier.23 While there are
clearly many exceptions to such generic rules, many have
been taken up widely for preliminary screening purposes,
notably in early drug development.
There are numerous examples of software (freely avail-
able and commercial) that can generate simple physico-
chemical properties for chemicals, apply rules-of-thumb
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Table 3. Summary information for example software for predicting properties, calculating similarity or performing read-across.
Software Website details and further information
ACD/PhysChem Suite http://www.acdlabs.com/products/percepta/
Prediction of properties: physico-chemical; ADME; toxicity.
ADMET Predictor http://www.simulations-plus.com/
Prediction of properties: physico-chemical; ADME; toxicity.
AMBIT http://cefic-lri.org/toolbox/ambit/
Freely available: incorporates extensive database, integrates models for toxicity prediction; provides a
workflow to support category formation and read-across.
AutoDock http://autodock.scripps.edu/
Freely available suite of automated docking tools to predict interaction between small molecules (e.g.
substrates or drug candidates) and receptors.
ChemMine Tools https://chemminetools.ucr.edu/
Freely available: tool for similarity analysis or clustering of chemicals based on physico-chemical or structural
similarity.
Cloe PK www.cyprotex.com





Derek: predicts toxicity from expert knowledge; Meteor: rule-based prediction of metabolites (customisable to
enable predictions for individual enzymes); Sarah: statistically-based prediction of mutagenicity.
EPISUITE http://www.epa.gov/opptintr/exposure/pubs/episuitedl.htm
Freely available suite of programs from the US EPA; prediction of properties: physico-chemical; dermal uptake;
toxicity to aquatic organisms (fish, Daphnia, algae).
KNIME https://www.knime.com/
Open platform enabling development of nodes for multiple applications, e.g. Indigo, CDK and RDKit
chemoinformatics tools for QSAR descriptor generation, 2-D and 3-D model building, conversion of





Computer-aided design platform: calculation of >400 descriptors; 3-D pharmacophore mapping; docking,
screening, etc.
Molinspiration http://www.molinspiration.com/
Freely available web tool: calculates Lipinksi Rule of Fives violations.
OCHEM https://ochem.eu/home/show.do
Freely available database; operates on the wiki principle; capacity to screen chemicals.against numerous
structural alerts for toxicity (human health and environmental).
OpenEye Applications https://www.eyesopen.com/lead-optimization
Molecular docking and screening tools, using 2-D and 3-D similarity measures, for lead optimisation.
QSAR Toolbox https://www.qsartoolbox.org/
Freely available software to support chemical hazard assessment; identifies structural and/or mechanistic
analogues for read-across; incorporates numerous databases; skin and liver metabolism simulators; profilers
(e.g. for DNA/protein binding).
Simcyp https://www.certara.com/simcyp-simulator/?ap¼Simcyp&UTM_LeadSource¼
Physiologically-based pharmacokinetic modelling; population simulations.
SwissADME http://www.swissadme.ch/
Freely available web tool for calculation of physico-chemical properties, ADME/PK parameters, drug-likeness,
etc.
ToxMatch https://sourceforge.net/projects/toxmatch/
Freely available software for similarity analysis; can be used for grouping chemicals into categories.
Toxtree http://toxtree.sourceforge.net/
Freely available software; prediction of a range of toxicity endpoints using decision trees.
VEGA HUB https://www.vegahub.eu/
Free available software; prediction of a range of toxicity endpoints using QSAR models.
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or cut-off criteria, and broadly classify chemicals into cate-
gorical classes (for example, poorly absorbed versus effec-
tively absorbed across the gastrointestinal tract; blood–
brain barrier penetrants versus non-penetrants, etc.). The
freely available web-based application SwissADME, from
the Swiss Institute of Bioinformatics (http://www.swis
sadme.ch/index.php), is one such example. Similarly,
Molinspiration (freely available at: http://www.molinspira
tion.com/) readily identifies chemicals with potential
Lipinski Rule of Fives violations. Table 3 provides further
examples of predictive software for a range of endpoints
that includes examples of SARs.
Structural alerts (SAs) are also derived from simple rela-
tionships between molecular features and known activity
(toxicity), and they can be used to screen chemicals for
potential hazard. In this approach, the molecular structures
of chemicals known to be associated with a specific toxicity
are investigated, in order to identify which sub-structural
features or fragments are associated with the activity. A
mechanistic rationale can then be posited, where possible.
These fragments can be used to define SAs, i.e. specific
molecular features that, if present in a chemical of interest,
are indicative of the potential to elicit a toxic effect. In
1988, Ashby and Tennant published a ‘poly-carcinogen’
molecule, i.e. a hypothetical molecular structure that incor-
porated the SAs for carcinogenicity that were known at the
time.24 Work has been ongoing in this area for decades, to
identify additional SAs associated with DNA binding, that
could be related to mutagenic/carcinogenic activity.25–27
Many SAs have also been defined to aid the identification
of chemicals with the potential for protein binding that may
be associated with skin and/or respiratory sensitisation.28–30
The relevant key concepts outlined in Figure 2 show two
examples of SAs associated with DNA and protein binding.
The presence of these functional groups in other chemicals
(for which test data are not available) indicates the potential
of that chemical to elicit toxicity via DNA or protein bind-
ing. When identifying SAs, it is important to be able to
rationalise the observed activity/toxicity in terms of the
mechanistic chemistry behind the chemical-biological inter-
action, in order to justify the prediction. The aromatic
amines provide an example of how such an effect can be
rationalised, as depicted in Figure 2. Aromatic amines can
undergo metabolism (via N-hydroxylation and O-acetyl
transferase) to form a reactive nitrenium ion. The electro-
philic nitrenium ion interacts with nucleophilic groups on
• Certain structural features may be associated with a specific mechanism of toxic acon giving rise to structural alerts.
• Many structural alerts have been idenfied associated with different toxic endpoints e.g. mutagenicity, skin
sensisaon, liver toxicity, kidney toxicity, phospholipidosis etc.
• Structural alerts may be grouped together to form profilers, used to assist read-across predicons of toxicity.
• The presence of the same alert in another chemical indicates the potenal for that chemical to elicit the same effect:
- Factors such as steric hindrance or differences in uptake, distribuon or metabolism can alter the likelihood of
the effect being observed.
- A parent molecule that does not possess an alert may undergo abioc transformaon or metabolism to a
molecule that does contain an alert and therefore elicit a toxic effect in vivo.
2a: Example structural alert showing an aromac amine (structural alert highlighted).
Aromac amines can be metabolised into electrophilic nitrenium ions that can react with nucleophilic sites within DNA
(denoted as Nu); this can lead to mutagenicity.
2b: Example structural alert showing an α,β-unsaturated aldehyde (structural alert highlighted).
α,β-unsaturated aldehydes are direct-acng electrophiles (meaning metabolism is not required) capable of reacng
with nucleophilic sites within proteins (denoted as Nu); in skin this can lead to skin sensisaon.
Figure 2. Key Concepts Box: Structural alerts associated with DNA and protein binding.
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DNA to form a DNA adduct, a process associated with
mutagenicity.
SAs for skin and respiratory sensitisation (associated with
allergic contact dermatitis and airway hypersensitivity,
respectively) are widely used within industry — for exam-
ple, to predict potential toxicity of personal care and house-
hold products. In drug development, alerts associated with
the formation of reactive metabolites, hepatotoxicity, etc. are
of major concern, as these are often associated with late
stage or even post-marketing withdrawal of drugs. Detailed
reviews of the definition, characterisation and mechanistic
rationalisation of SAs associated with the formation of reac-
tive metabolites, mitochondrial toxicity, phospholipidosis
and hepatotoxicity have all been published previously.31–37
However, it is important to note that the presence of a struc-
tural alert does not necessarily equate with a biological
response. Modulating factors may ameliorate or potentiate
the response in vivo — for example, a compound with an
alert may not be bioavailable or, from a chemical structure
perspective, significant steric hindrance may interfere with
access to an active site. Also, it is possible that metabolic
deactivation/activation may render a potentially toxic chem-
ical non-toxic, and vice versa. SAs can be grouped together
to form ‘profilers’, with chemicals then being screened
against these profilers to identify groups of chemicals that
share common feature(s). This concept is discussed further
below, in relation to the functionality of the QSAR Toolbox.
SAs have also been encoded within several predictive
toxicity software and web-based applications, examples of
which are provided in Table 3. Toxtree uses SAs, decision
trees and QSARs to predict toxic hazards, reactivity and
potential metabolism. It encodes the Cramer rules and the
revised Cramer decision tree, which relate to oral systemic
toxicity.38 Through the use of structural information, che-
micals are allocated to a toxicity class (where Class I relates
to low toxicity, Class II intermediate and Class III high
toxicity). Within Toxtree, the Kroes Threshold of Toxico-
logical Concern (TTC) decision tree can be used to estab-
lish whether a substance can be assessed for oral systemic
toxicity by using the TTC approach.39 TTC is a concept
that establishes the level of exposure for all chemicals (with
or without toxicity data) below which there would be no
appreciable risk to human health. The method incorporates
Cramer classification rules and rules for prediction of gen-
otoxic carcinogens; it also requires information relating to
the estimated daily intake.
The Verhaar scheme for predicting mechanism of
action of fish acute toxicity is also encoded within Tox-
tree. Chemicals are placed into classes I–V, with Class I
representing non-polar narcotics, Class II polar narcotics,
Class III reactive chemicals and Class IV specifically act-
ing chemicals; Class V is used for chemicals that cannot
be allocated to classes I–IV.40 Other functionalities within
Toxtree use SAs and physico-chemical information to
predict potential for carcinogenicity (genotoxic and non-
genotoxic), mutagenicity, skin sensitisation, protein and
DNA binding, as well as skin and eye irritation/corrosion,
biodegradability and cytochrome P450-mediated drug
metabolism.
OCHEM is another freely available web tool, which
includes (in addition to the other capabilities described
herein) compilations of SAs associated with different toxi-
cities (e.g. skin sensitisation or environmental endpoints)
against which a target chemical can be screened. If an alert
is identified within the target chemical, further information
on the alert is provided, such as the literature source(s) from
where the alert information was derived.
The advantages of using SAs are that they are transpar-
ent and can be readily interpretable, if developed from a
mechanistic basis. Work is ongoing to identify further
alerts associated with toxic effects and to understand the
mechanisms behind the interactions. One drawback of the
approach relates to how the absence of any SAs for toxicity
within a chemical’s structure can be interpreted, as this
cannot (usually) be considered as evidence of safety.
The use of screening to detect potential toxicity in the
early stages of product development (including personal
care products, manufacturing intermediates or drugs)
means that those formulations likely to be associated with
significant toxicity can be identified earlier in the develop-
ment process. Only candidates that are more likely to be
successful are taken forward, while those presenting toxi-
city issues are discontinued. This ultimately reduces the
number of chemicals tested on animals.
Quantitative structure–activity
relationships (QSARs)
Since the pioneering work of Hansch et al. in 1962,41 quan-
titative structure–activity relationships (QSARs) have been
used to demonstrate the quantitative relationship between
properties of interest for a chemical and descriptors that are
derived from its chemical structure. Such models have been
applied to the prediction of (eco)toxicity and drug potency,
and have also been used to predict physico-chemical prop-
erties (where they are referred to as quantitative structure–
property relationship (QSPR) models).
The philosophy of QSAR or QSPR modelling can be
explained in relation to its three constitutional require-
ments, outlined below:
The first requirement is for quantitative measures of the
property of the chemical that is to be modelled (i.e. endpoint
values), for a series of related chemicals. Endpoints include:
biological activity or toxicity — for example, half maximal
effective concentration for a drug (EC50), or lethal dose for
50% of test organisms (LD50); ADME parameters, such as
the percentage of human intestinal absorption (% HIA); or
physico-chemical properties, such as melting point.
The second requirement is to generate, or obtain, descrip-
tors derived from knowledge of the chemicals’ structures for
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the series of chemicals used to generate the model. It is now
possible to generate thousands of descriptors, and care must
be taken to ensure that spurious relationships are not devel-
oped by the incorporation of too many, or irrelevant, descrip-
tors into the model. Generally, readily interpretable
descriptors are favoured in generating QSARs, particularly
where these are used to inform safety assessment or regula-
tory submissions. However, there are many examples of
QSARs based on statistical correlations. Although these can
be difficult to interpret, they can be useful screens in early
product development. Frequently used descriptors include
those relating to partitioning — for example, the logarithm
of the octanol:water partition coefficient (log P), aqueous
solubility; and tissue:blood partition coefficients. These indi-
cate relative lipophilicity/hydrophilicity of chemicals, and
have been shown to correlate with the ability of chemicals
to traverse biological membranes and hence reach a site of
action. Size and shape descriptors — for example, molar
volume, molecular weight (M Wt), topological indices and
surface area are often incorporated, as they may reflect the
ability of the chemical to reach a site of action or interact
with a target in the body. Electronic effects, such as hydro-
gen bonding ability, Energy of the Highest Occupied Mole-
cular Orbital (EHOMO), Energy of the Lowest Unoccupied
Molecular Orbital (ELUMO) and dipole moment, can be used
to indicate potential reactivity or binding at an active site.
For example, Schwöbel et al.42 reviewed the use of descrip-
tors, based on electrophilic reactivity, for predicting toxicity
associated with the interaction of biological nucleophiles
with electrophilic xenobiotics (e.g. DNA binding and skin
sensitisation).
The final requirement of a QSAR is a statistical tech-
nique that is used to demonstrate the correlation between
the activity (toxicity, or other property of interest) with the
descriptor values. Many statistical methods are used, rang-
ing from simple linear regression, where a single descriptor
is associated with an activity, or multiple linear regression,
where several descriptors are used. The equation below
shows an example of a simple, readily interpretable QSAR





• Outliers – poorly fit to model, therefore maybe excluded
An example QSAR using one descriptor (log P) that shows a posive correlaon with toxicity:
Toxicity = 0.75 Log P – 2.00
n = 13  r2 = 0.95
n = no of chemicals used in the model (i.e. 13); r2 = 0.95 indicates 95% of variability in model
is explained by the variaon in log P
• QSARs are mathemacal relaonships between physico-chemical or structural
descriptors of a series of chemicals and their acvity (toxicity).
• Chemicals used to build a QSAR should ideally have the same mechanism of acon.
• A QSAR can only be used to make predicons for chemicals that fall within its applicability
domain (the region of chemical structural/property space covered by the model).
• The OECD principles for the validaon of QSARs specify that QSARs should be associated
with (i) a defined endpoint, (ii) an unambiguous algorithm, (iii) robust stascs, (iv) a
defined applicability domain and (v) be mechaniscally interpretable – where possible.
• Many exisng QSARs have not undergone formal validaon but can provide useful
predicons provided their suitability for specific chemicals and purposes is ascertained.
Figure 3. Key Concepts Box: Quantitative structure–activity relationships (QSARs).
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where Kp is the skin permeability coefficient.43 Here, Kp is
shown to have a positive correlation with log P and a neg-
ative correlation with molecular weight.
Log Kp ¼ 0:71 log P  0:0061M Wt  6:3
N ¼ 93; R2 ¼ 0.67
The square of the correlation coefficient (or coefficient of
variability), R2, indicates the variability in the property of
interest (Kp) that is accounted for by the descriptors (log P
and M Wt). In correlating an individual descriptor with a
property of interest, an r value of 1 demonstrates a perfect
positive correlation, whereas a value of –1 indicates a per-
fect negative correlation. Correlation coefficient values
above 0.7 are often quoted as indicating a useful model.
However, definitive rules are not realistic, as it is highly
dependent on the nature of the data. R values close to 1 are
generally unrealistic for models predicting biological activ-
ity, because of the inherent experimental variability in the
data used to generate the model, as referenced above.18
Once a reliable QSAR model has been generated with
training set data, a test set can be used to assess the pre-
dictivity of the model for chemicals outside of the training
set. R2CV (or Q
2) is the cross validated R2 value that is
obtained by using the model to predict the activity of a test
set, either by withholding part of the training set during the
model building process (internal validation) or by using an
external dataset (external validation). R2CV values of 0.6
are often referred to as useful but, again, caution should be
used in applying rigid definitions.
Models should only be used for making predictions for
those chemicals that fall within the applicability domain of
the model — a concept which is discussed further below.
Outliers in QSAR models (i.e. chemicals that are poorly
fitted to the model) require investigation. These outliers
may indicate that alternative mechanisms of action are
involved in the process, which are not accounted for by the
model, or that a data point is erroneous, in which case it
should be discounted. The principles of internal and exter-
nal validation of QSAR models and a comparison of the
validation methods that may be applied have been
described previously.44
The immutable truth in statistics is that correlation is not
the same as causation. If a correlation exists between
descriptors and properties, it does not necessarily mean that
the change in one causes the change in the other. A causal
relationship needs to be demonstrated, as correlation may
be driven by another external factor. There is a strong
correlation between total volume of tea consumed and the
wisdom of humans, however (disappointingly), both of
these are in fact determined by age — tea drinking does
not lead to wisdom. Misinterpreting the difference between
correlation and causation, and attempting to make predic-
tions for chemicals outside of the applicability domain of
the model, are common reasons why QSAR models are
believed to ‘fail’. With appropriate use, models can provide
insight into mechanisms of action and provide useful pre-
dictions where endpoint data are missing for certain che-
micals. Cherkasov et al.45 provide a detailed history of the
development of QSAR models, trends in use, emerging
applications and guidance for best practice in developing
and evaluating QSARs. A summary of the key concepts of
simple QSAR models is given in Figure 3.
As the amount of data available (both endpoint and
descriptor) has expanded exponentially, more advanced
modelling techniques and machine learning methods have
been employed to investigate potential patterns within
these data. Non-linear relationships between descriptors
and endpoints have been derived using artificial neural net-
works (ANNs), which are designed to mimic the learning
processes of the human brain. ANNs comprise an input
layer, that is connected to a sequence of ‘hidden’ nodes,
in turn connected to an output layer. By adjusting the
weighting of the hidden nodes, statistically significant cor-
relations can be developed between the descriptors and an
endpoint of interest; endpoint data can be used to train the
network to minimise prediction error (supervised learning)
or patterns between descriptors can be investigated without
the use of endpoint data (unsupervised learning).
More recently, deep learning neural networks (DNNs)
have been used to simultaneously predict more than one
endpoint of interest from a collection of QSAR datasets. By
apparently using the signal from adjacent chemicals
involved in other QSAR tasks (i.e. where one QSAR task
is embedded within several other QSAR tasks) improved
predictions may be possible; however, this is not always the
case.46 Support vector machines (SVMs) have also been
used to identify non-linear relationships, for example, by
defining the hyperplane (boundary between regions) that
provides the best separation between different classes of
chemicals. Many other methods have been used for deriv-
ing non-linear relationships between descriptors and end-
points. While these have shown some success in predictive
modelling, they are often considered as ‘black box’ models
because the methodology is opaque. These may be useful
for investigating datasets or for preliminary categorisation.
However, in terms of chemical safety assessment, such
methods are disfavoured because of their lack of interpret-
ability. In the same way that data are investigated to assess
their suitability for a given purpose, the same philosophy
applies to selecting the most appropriate modelling method
for a given purpose.
Three-dimensional approaches
QSAR models based on simple descriptors (e.g. log P,
reactivity, etc.) are useful for a range of endpoints, such
as aquatic toxicity or gastrointestinal absorption, etc. How-
ever, for certain endpoints that result from receptor binding
interactions, such as endocrine disruption, 3-D descriptors
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may be more appropriate.47 Pharmacophores (relating to
drug activity) or toxicophores (relating to toxicant activity)
describe the relative spatial orientation of key molecular
features (such as hydrogen bond-donating or accepting
groups) within a molecule that align with the complemen-
tary region of the target receptor. Three-dimensional mod-
elling enables chemicals to be classed as potentially active
or inactive, depending on the degree of fit or binding poten-
tial to the target. This approach has been used to develop
and rationalise a pharmacophore for ligands associated with
PPARg activation, a mechanism involved in liver steatosis.48
Fitting to this pharmacophore could be used as a screening
tool to identify potential PPARg agonists. A drawback of 3-
D QSAR models is that they can be computationally expen-
sive, as conformational flexibility of chemicals needs to be
accounted for, and a suitable (energetically-minimised) con-
formation selected to assess binding potential. Molecular
docking is a widely used in silico method to predict interac-
tions between ligands and targets. Examples of both freely
available (e.g. AutoDock) and commercial (e.g. Molecular
Operating Environment and OpenEye Scientific) software
for 3-D analysis are indicated in Table 3.
Predicting categorical data
QSAR analysis, as described above, is useful for deriving
models for continuous data (for example, LD50 values). For
certain endpoints, a categorised approach may be more
appropriate. In this context, local lymph node assay
(LLNA) data for determining skin sensitisation potential
is often used to create discrete classes. These may be binary
(such as sensitiser versus non-sensitiser) or provide an indi-
cation of relative potency (such as non, weak, moderate,
strong or extreme sensitisers) based on discretisation (cate-
gorisation) of experimental data. Classification-based mod-
els can use molecular-based or similarity-based descriptors
to assign chemicals to the appropriate class. In discriminant
analysis, relevant properties can be used to distribute the
chemicals in two or higher-dimensional space. A line or
plane (discriminant function) is then used to separate the
different classes of chemicals; cut-off values for specific
properties can also be used to differentiate members of
different classes. In a recent study, discretisation of enzyme
inhibitor data and knowledge of molecular properties was
used to develop a classification-based model to assign inhi-
bitors of beta-secretase (BACE1) into one of two classes
(i.e. high activity or little/no activity) to aid the identifica-
tion of potential therapeutic agents for Alzheimer’s dis-
ease.49 In the k-nearest neighbour (k-NN) approach,
chemicals are placed into classes based on their similarity
to other chemicals within the class (concepts of chemical
similarity are discussed further below). Kovarich et al.50
describe the use of k-NN to allocate brominated flame
retardants to classes of ‘actives’ and ‘inactives’, based on
their potential to elicit endocrine disruption.
Predictive software
There are many examples where existing QSAR models
have been incorporated within predictive software. For
example, EPISUITE (freely available from the US EPA)
enables a range of endpoints to be predicted, based on the
chemical’s structure and application of a suite of integral
QSAR models. The endpoints include physico-chemical
properties, such as log P, aqueous solubility, Henry’s law
constant, dermal uptake and toxicity to environmental spe-
cies (i.e. via the ECOSAR application that predicts acute
and chronic toxicity of chemicals towards algae, aquatic
invertebrates and fish). VEGA HUB also provides access
to a range of freely available QSAR models that were either
developed as part one of the many EU projects (such as
CAESAR), or obtained from TEST (the Toxicity Estima-
tion Software Tool from the US EPA). There are four cate-
gories of predictive models, namely:
– toxicity (e.g. mutagenicity, carcinogenicity, devel-
opmental and reproductive toxicity, oestrogen
receptor binding, skin sensitisation and hepatotoxi-
city models);
– ecotoxicity (e.g. fish, Daphnia and bee acute toxicity
models);
– environmental fate (e.g. bioconcentration, half-life,
biodegradability and persistence models); and
– physico-chemical property models (e.g. log P
prediction).
Detailed and accurate reporting of QSAR models and pre-
dictions derived therefrom are important, if the predictions
are to be used with confidence, especially for regulatory
submissions. VEGA, as well as other software, provides
detailed reports based on a standardised QSAR Model
Reporting Format (QMRF). Table 3 provides further exam-
ples of software that are widely used to predict physico-
chemical properties, ADME information or toxicity. These
are representative examples to indicate the capabilities of
such software, the list is by no means exhaustive. As an
output of the ANTARES project (Alternative Non-Testing
methods Assessed for REACH Substances), a comprehen-
sive list of software available for predicting physico-
chemical, (eco)toxicological, environmental fate and ADME
properties was previously reported (http://www.antares-life.
eu/index.php?sec¼modellist). A more recent review by Kar
and Leszczynski51 describes a range of freely available tools
for ADMET prediction. The Computational Chemistry List
(http://www.ccl.net/chemistry/links/software/index.shtml)
also provides a large compilation of available resources for
QSAR modelling. Also noteworthy, is the open source
KNIME platform, through which a community of users has
developed and shared numerous ‘nodes’ for a wide range of
chemoinformatic applications. More information (and
download access) is available at https://www.knime.com/.
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Chemical structural similarity
It is often observed that similar chemicals exhibit similar
effects. Therefore, despite the caveats noted above, there is
a desire to identify which chemicals are similar, to enable
predictions to be made for chemicals lacking data, from
those with data. It is essential to understand that no
• Read-across is the process by which informaon from one, or more, data-rich, source chemicals is used to infer
informaon for one or more target chemicals (for which data are lacking).
• Read-across requires the idenficaon of analogues that are considered similar to the target (refer to Figure 4 )
• The jusficaon of analogue selecon (based on appropriate measures of similarity) is key to a successful read-across
argument.
• Incorporaon of toxicokinec data in read across predicons (parcularly in respect of metabolic potenal) is a key factor
in reducing uncertainty in predicons.
• According to the European Chemicals Agency (ECHA), read-across is the most common alternave method used to supply
informaon in REACH dossiers
Figure 5. Key Concepts Box: Read-across.
• It is important to be able to idenfy chemicals that are similar as similar chemicals oen have similar acvies .
- there are excepons to this where apparently similar chemicals show very different acvies (e.g acvity cliffs).
• No chemical can be considered absolutely similar to another, only similar in respect to a given property: e.g physico-chemical
property, structural similarity, formaon of a common metabolites, mechanism of (toxic) acon etc.
• Chemical fingerprints are oen used to idenfy similar chemicals; a bitstring is generated for each chemical based on the
presence “1” or absence “0” of parcular chemical feature (key). Bitstrings are compared using a mathemacal formula (e.g.
Tanimoto coefficient) to find the degree of overlap between bitstrings for different chemicals.
• An illustrave example for calculang the Tanimoto coefficient (a metric to compare bitstrings) is shown below.
• The closer to 1 the measure of similarity the more similar are the chemicals, the closer to 0 the less similar.
• Similarity values above 0.6 or 0.7 are oen used to categorise chemicals as similar, but these are arbitrary values.





0 1 1 0 0 1 …..
Keys searched for in structure:  
chlorine phenol carbonyl methoxy nitro aromac…………
0 1 1 1 0 1 …..
a = no of bits set to 1 in chemical a (i.e. 3) b = no of bits set to 1 in chemical b (i.e. 4)
c = no of bits set to 1 in chemicals a and b (i.e. 3)






• Note this is an illustrave example only; usually hundreds of keys are used and the bits compared.
• Choosing different keys to seek within the chemical structure and/or different formulae to compare bitstrings, results in
different values for the measure of similarity between two chemicals.
Keys searched for in structure:  
chlorine phenol carbonyl methoxy nitro aromac…………
carbonylphenol
Figure 4. Key Concepts Box: Similarity and fingerprints.
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chemical can be absolutely similar to another, only similar
with respect to a given property (or properties). Chemical
fingerprinting is a technique that is commonly used to iden-
tify chemicals that are structurally similar. To generate a
chemical fingerprint, the presence or absence of specific
structural features (keys) within a molecule is indicated by
‘1’ or ‘0’, respectively. This enables a bitstring to be gen-
erated for every chemical within a group. The calculated
degree of similarity between chemicals depends, firstly,
upon which structural features (keys) are sought within the
structure. Many different sets of keys are used for this
purpose, with different numbers and types of features
sought. For example, the fingerprinting algorithm available
through the PubChem website uses 881 keys, Daylight fin-
gerprinting uses 1024 keys and MACCS uses 166 keys.
Once the fingerprints have been generated for the chemi-
cals of interest, a mathematical formula is used to calculate
the degree of overlap between the bits occurring in the
fingerprints of different chemicals. The calculated degree
of similarity between chemicals depends, secondly, on
which mathematical formula is used to calculate the over-
lap. The Tanimoto coefficient is commonly used for this
purpose. However, there are many other methods (as sum-
marised by Daylight Chemical Information Systems Inc.;
https://www.daylight.com/dayhtml/doc/theory/theory.fin
ger.html).
The key concepts illustrated in Figure 4 include an
example calculation for the generation of similarity indices
using the Tanimoto coefficient. (Note that, in this case, a
few example bits only have been included for illustrative
purposes. Typically, hundreds of bits are used.) Chemicals
with an index of similarity (e.g. Tanimoto coefficient)
close to 1 are considered similar, values approaching 0
indicate little or no similarity. Tanimoto coefficients of
0.6 or 0.7 have been used as cut-off values to differentiate
similar or dissimilar chemicals — however, these are arbi-
trary and other values may be more appropriate in certain
circumstances. The selection of bit strings to compare (e.g.
those generated by MACCS, PubChem fingerprints, etc.)
and the method used to compare the bitstrings (e.g. Tani-
moto, Euclid, Pearson, etc.) can give very different results
for the calculated degree of similarity. This concept was
exemplified by Mellor et al., who demonstrated (among
many other examples) that for 3-methyl-6-n-butylphenol
and 2,6-di-tert-butylphenol, using CDK FCFP6 type fin-
gerprints, the Tanimoto coefficient of similarity was 0.26
(i.e. dissimilar), whereas using CDK PubChem finger-
prints, the Tanimoto coefficient was 0.88 (i.e. similar).52
As yet, there is no consensus as to which is the most appro-
priate similarity metric to use. It is likely that different
metrics will be appropriate for different scenarios, which
is an important consideration in view of the fact that
knowledge available for similar chemicals is increasingly
used to inform data gap filling. The KNIME platform
(https://www.knime.com/) provides nodes for molecular
fingerprinting and analysis by using a range of similarity
metrics.
Analogues, grouping and read-across
In recent years, a conceptually simplistic process has
become prevalent in industrial and regulatory settings —
i.e. the use of read-across to assist chemical safety assess-
ment. Read-across is the process by which endpoint infor-
mation for one or more data-rich (source) chemicals is used
to make predictions for one or more data-poor (target) che-
micals, that are considered to be similar (as illustrated in
Figure 5).
In the analogue approach, one (or few) highly similar
chemicals are used to perform read-across from source to
target chemicals. Grouping is a process whereby chemicals
that share one or more common properties are placed
together in groups or ‘categories’ of related chemicals.
Where information is available for some members of the
group, this is used to make inferences for other group mem-
bers. Key to identifying analogues, generating groups or
performing read-across is identifying which chemicals can
be considered to be similar. Similarity may be considered
in terms of chemical fingerprints (as described above),
being part of the same chemical class (e.g. varying in car-
bon chain length), physico-chemical properties, presence
or absence of specific structural features (e.g. SAs) and/
or mechanism of action.
Forming a group on the basis that all chemicals share a
common mechanism of action, is a robust method for
grouping, where the mechanism of toxic action is known
— for example, this grouping could be based on the pres-
ence of a relevant structural alert that is known to be asso-
ciated with a specific toxicity. If the mechanism is
unknown, then analogues may be selected by using simi-
larity metrics. As there is no single ‘best’ method to deter-
mine similarity, pragmatically it may be appropriate to use
several similarity metrics initially, and then rationalise ana-
logue selection based on additional criteria. Software to
identify structurally similar chemicals (using a range of
metrics) has been available for many years — for example,
ToxMatch (from Ideaconsult) and the Compound Similar-
ity workbench from ChemMine Tools (see Table 3). These
can provide quantitative measures of similarity between
different chemicals, enabling appropriate groups to be
formed. In order to make a successful read-across predic-
tion for an in vivo response, analogue selection should take
into consideration similarity, not only of chemical struc-
ture, but more importantly, similarity in mechanism of
(toxic) action and ADME profile (i.e. pharmacokinetics
or toxicokinetics).
The acceptability of read-across predictions relies upon
full justification and accurate documentation of how the
appropriate source chemicals, from which the prediction
for the target was made, were selected. Hence, justifying
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the criteria by which ‘similar’ chemicals have been selected
for read-across is of paramount importance. Extensive gui-
dance on how to perform read-across based on analogues or
grouping, as well as on how to record the requisite infor-
mation, has been produced by the Organisation for Eco-
nomic Co-operation and Development (OECD).53 The
read-across assessment framework (RAAF) from the Eur-
opean Chemicals Agency (ECHA) provides guidance on
how read-across predictions can be evaluated, to ensure
suitability for regulatory submission. Originally devised for
internal use by ECHA, this has been made publicly available
to assist those submitting dossiers incorporating read-across,
to help ensure the appropriateness of their argumentation.
The process is exemplified through a series of ‘scenarios’
comprising different ‘assessment elements’ against which
the validity of the read-across is judged.54
The past five years has seen a plethora of articles on how
to perform, and document, read-across predictions (for reg-
ulatory purposes), particularly the identification and justi-
fication of analogue selection.53–55 More recent
publications have focused on: lessons learned from read-
across submissions to ECHA, highlighting pitfalls and rea-
sons for rejection;56 how uncertainty in predictions can be
characterised, reported and reduced;57 and how to select
analogues accounting for pharmacokinetic/toxicokinetic
similarity,58–61 all with the aim of increasing regulatory
acceptance of read-across predictions. Bespoke tools for
performing read-across have also been developed. AMBIT
(from the European Chemical Industry Council’s Long
Range Initiative, Cefic-LRI) includes an extensive, search-
able database, as well as integrating models for toxicity
prediction (i.e. Toxtree models). A comprehensive assess-
ment workflow can be used within AMBIT to identify
source chemicals for a given target, assist with read-
across and generate standardised reports; the features of
AMBIT are summarised in Table 3.
QSAR Toolbox
The QSAR Toolbox (formerly the OECD QSAR Toolbox)
is a freely available, prototypical tool for performing read-
across, designed for use by industry and regulators.62 The
first version was released in 2008 and, following multiple
improvements and updates, version 4.4.1 was released in
April 2020. This software was designed specifically for the
purpose of grouping chemicals together into rationally-
based categories and performing read-across to fill gaps
in (eco)toxicity data for hazard assessment. Detailed step-
• The QSAR Toolbox is freely available and specifically designed to assist with grouping chemicals for read-across in
order to fill gaps in (eco)toxicological data.
• It follows a set workflow to profile chemicals enabling raonal formaon of groups and the use of endpoint data
for source chemicals in the groups to make predicons for target chemicals.
• Many databases have been donated to the Toolbox, therefore it is also an extensive resource for data.
• It incorporates skin and liver metabolism simulators as well as known metabolic data.
Input target chemical (data poor)




Develop and refine category







Figure 6. Key Concepts Box: Workflow of the QSAR Toolbox.
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by-step user guidance documents, online tutorials and
example case studies are available with the software down-
load files (from https://qsartoolbox.org/). The Toolbox fol-
lows a logical workflow, whereby a query (target) chemical
is input and can then be profiled using one of the many
profilers incorporated into the system. These profilers are
categorised as empiric, toxicological endpoint specific or
mechanistic (i.e. used to identify functional groups or fea-
tures associated with a structural alert, as described above).
Many databases have been donated to the Toolbox project,
and as a result it also represents a useful stand-alone data-
base for physico-chemical property toxicity data and meta-
bolic information.
The Toolbox enables rationally-based chemical cate-
gories to be developed. These can be further refined, if
necessary, to ensure that a suitable sub-category is formed
— i.e. that the structures of chemicals in the group are
sufficiently similar and that the group is representative of
the query (target) chemical for which the read-across pre-
diction is to be made. Chemicals within the category for
which data are known (source chemicals) are used to infer
the activity of the target chemical(s) using read-across. The
Toolbox includes functionalities for predicting skin and
liver metabolism, in addition to the known metabolic infor-
mation in the database. The formation of common metabo-
lites is an acceptable reason to group chemicals, and the
metabolites themselves may be profiled (e.g. for the pres-
ence of particular functional groups or SAs). As the Tool-
box is continually updated with information and
functionalities, the resulting software has become quite
complex for novice users. Consequently, automated work-
flows have now been developed for acute aquatic toxicity
and skin sensitisation, enabling non-experts to generate
predictions with minimal interaction. Standardised work-
flows, requiring the user to select relevant options based
upon their judgement, are available for more experienced
users.63 Key to a successful read-across is the complete,
transparent recording and documentation of the process of
category formation. These features are embedded in the
reporting module of the QSAR Toolbox, to ensure the pre-
diction has been adequately justified. Software to assist
with read-across is also summarised in Table 3, and the
generic workflow of the Toolbox is represented in Figure 6.
Evaluation of in silico models
In silico models, and predictions based upon their applica-
tion, should be evaluated to ensure the quality of the model
and the level of confidence in the predictions obtained. In
2003, the OECD established an Expert Group on QSARs,
and in 2004 the OECD member countries agreed on the
OECD Principles for the Validation, for Regulatory Pur-
poses, of (Q)SAR Models.64 The Principles state that “to
facilitate the consideration of a (Q)SAR model for
regulatory purposes, it should be associated with the fol-
lowing information:
1. a defined endpoint;
2. an unambiguous algorithm;
3. a defined domain of applicability;
4. appropriate measures of goodness-of-fit, robustness
and predictivity;
5. a mechanistic interpretation, if possible.”
While the terminology formally refers to QSARs, the
Principles are equally valid for evaluating other types of
in silico models.
It is clear that a model must be derived for a specific
endpoint; however, the relevance of the endpoint to the
outcome of interest must also be established. For example,
many models have been derived to predict mutagenicity,
and the results are compared to those from the Ames muta-
genicity assay. However, the true endpoint of interest is
quite often carcinogenic potential in humans; therefore, the
relevance of the endpoint must be considered. Chemicals
that are predicted to be mutagenic may ultimately lead to
carcinogenicity, but there are many reasons why this might
not occur (e.g. metabolism to a non-mutagenic entity or
compensatory pathways in vivo). Similarly, models that are
based on the results of a rodent carcinogenicity assay may
not be predictive of toxicity to humans. With respect to the
first of the OECD Principles, the endpoint should be both
well-defined and relevant.
Algorithms used to generate in silico models, such as
multiple-linear regression or SAs, are generally unambig-
uous and readily reproduced. In moving to more complex
modelling methods, such as Support Vector Machine
(SVM) learning or ANN, the algorithms may become less
transparent or difficult to reproduce, and there is a danger
of over-fitting data. Although complex models can play a
role in evincing subtle relationships within datasets that
may, for example, lead to alternative directions in product
development, the lack of transparency constrains their use
for regulatory safety assessment.
The third OECD Principle captures the concept that
(Q)SARs cannot be applied universally to all chemicals,
only to those within their applicability domain. This can
be defined as the physico-chemical, structural or mechan-
istic region of chemical space (represented by the chemi-
cals in the training set) for which reliable predictions can be
made. For example, if the training set chemicals all had a
log P value below 2, the model is unlikely to be reliable for
chemicals of significantly higher log P or for chemicals
with more diverse functionalities than those of the training
set.
Where models for biological activity (toxicity) are used
for prediction, the chemicals used to develop the model
should act via the same mode or mechanism of action.
Inappropriate use is one of the most common reasons why
18 Alternatives to Laboratory Animals XX(X)
in silico models produce unreliable predictions. As the
model user must determine the suitability of the model for
a given purpose, adequate documentation of the model —
for example, inclusion of the training/test set data, a
detailed description of the algorithm and model perfor-
mance statistics — is vital. A means of addressing these
issues with regard to the use of in silico models is to char-
acterise their uncertainties, as well as areas of bias and
variability; schemes have been developed to this effect, for
both read-across and QSARs.57,65 Uncertainties in model-
ling, and the methods by which this may be evaluated, are
not restricted to in silico models for toxicity prediction.
Uncertainties can arise from a range of factors, including
measurement error or inherent randomness of the system.
Causes of uncertainty in modelling, and how this uncer-
tainty may be described, evaluated and communicated, has
been explored across a range of disciplines.66,67 These stud-
ies have largely drawn upon the better understanding of
uncertainties in risk assessment. The definition of uncer-
tainties should not be seen as a means to definitively vali-
date an in silico approach (although it can assist in that), but
rather it should be seen as a way to identify areas of weak-
ness where more information or evidence may be required.
The long-term aim is to be able to define the level of
uncertainty that may be acceptable for a particular purpose,
and have the means to determine if a particular model
reaches the threshold of acceptability, and, if not, what is
required in order for it to reach that level.
In silico tools as components of integrated
frameworks
In silico tools are generally not capable of acting as one-
for-one replacements for in vivo toxicity assays,
although they are now accepted for the assessment of
mutagenic impurities under the International Council for
Harmonisation of Technical Requirements for Pharma-
ceuticals for Human Use (ICH) M7 guidelines.68 More
often, these tools provide pieces of relevant information
that can help to build a complete mechanistic under-
standing of the processes involved when a chemical
interacts with a biological system. Predictions from
in silico models are more useful when used in conjunc-
tion with other methods, but this requires a flexible
framework through which relevant chemical and biolo-
gical information can be integrated.
Chemical-Specific Information
Physicochemical properes
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In a PBK model informaon about (i) the chemical and (ii) the
physiological / anatomical informaon for the species of
interest are used as input parameters. Differenal equaons
are used to describe the rate of change of concentraon of
chemical in blood entering and leaving the organs. This allows a
concentraon-me curve to be generated for any organ of
interest. Simpler models use fewer organs or “lump” together
those with similar properes. More complex models can include
sub-compartments within organs. Organ-level concentraons
are more relevant to acvity (toxicity) than external dose.
Figure 7. Key Concepts Box: Physiologically-based (PBK) models.
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For safety assessment, evidence from a range of sources
can be compiled on a case-by-case, weight-of-evidence
approach. Integrated Testing Strategies (ITS) or Integrated
Approaches to Testing and Assessment (IATA) have been
used to organise existing information that is relevant to
toxicity assessment, in an effectively logical manner. Such
approaches make it easier to determine whether there is
sufficient information available on which to base a deci-
sion, or whether further evidence is required — and, if so,
how testing should best be directed.69
The in silico protocol for skin sensitisation describes a
framework for the integration of results from in silico
methods, as well as from experimental sources, to help
identify potential sensitisers. The framework is a consen-
sus on how to predict skin sensitisation derived from the
experience of 39 cross-industry organisations.70 Further
integration of approaches and techniques is inevitable,
with modelling being supported, as appropriate, by in
vitro, HTS, organ-on-a-chip, data technologies, etc. For
instance, the International Cooperation on Cosmetics
Regulation (ICCR) has proposed a set of principles for
the Next Generation Risk Assessment.71 The principles are
based on exposure and an understanding of mode/mechan-
ism of action. They include computational approaches
such as the Threshold of Toxicological Concern (TTC)
and evaluation of exposure, before a more detailed assess-
ment of toxicodynamics is undertaken. These comple-
ment, and to some extent extend, the ab initio
approaches to risk assessment which are intended for use
when read-across is not possible.72
Physiologically-based kinetic models
As biological response is determined by a combination of
intrinsic activity and the concentration–time profile of the
chemical at the relevant site, an important component of
integrating approaches is knowledge of the spatio-temporal
distribution of chemicals within the organism of interest.
Physiologically-based kinetic (PBK) models are increas-
ingly being used to provide information for such approaches,
in addition to their traditional use in drug development and
designing dosing regimen. Historically, physiologically-
based pharmacokinetic (PBPK) models were developed
within the pharmaceutical industry to describe the concen-
tration–time profiles of drugs in the blood and/or organs of
interest. However, the methodology is equally applicable
to toxicants, giving rise to the term physiology-based tox-
icokinetic modelling (PBTK). Therefore, the terms PBK,
PBPK and PBTK are commonly encountered. These mod-
els help to quantify the amount of chemical reaching a
target site (the internal dose), which is more relevant for
predicting activity than considering the external dose to
which an organism is exposed.
In a PBK model (as depicted in Figure 7) the body is
considered as a network of compartments (organs) linked
via the blood supply. The amount of chemical entering and
leaving the organ over time is calculated by using differen-
tial equations from which organ level concentration–time
profiles can be generated. Organs may be ‘lumped’ together
into classes (e.g. highly perfused or poorly perfused organs
are considered as groups) to simplify the modelling, or each
individual organ may be considered separately. The models
use information on the chemical (e.g. molecular weight,
aqueous solubility, lipophilicity, plasma protein binding
and tissue:plasma partitioning behaviour) and information
on the biological system (e.g. organ weights, volumes,
blood flows, capacity for metabolism or excretion).
Although data-hungry to generate and evaluate (ideally by
using kinetic parameters measured in the species of interest),
such models are highly adaptable — e.g. organ volumes/
blood flow can be altered to represent different species or
members of a population within a species, or metabolic
capability can be modified to represent different species,
age groups or diseased individuals. Concentration–time
profiles based on external exposure can be derived (for-
ward dosimetry), and species-to-species extrapolation or
individual-to-individual extrapolation within a species,
are both possible.
Reverse dosimetry (dose reconstruction) is the process
by which external exposure is derived from observed con-
centrations in vivo, such as values from biomonitoring data.
Quantitative in vitro to in vivo extrapolation (QIVIVE)
simulates concentration in the blood (or tissues) to deter-
mine the in vivo dose level that results in the concentration
in the blood (or tissues) equivalent to the concentration at
which an effect was observed in vitro. The area under the
concentration–time curve (AUC) or the maximum concen-
tration in the tissue, derived by the models, can be quanti-
tatively correlated with biological response in a
pharmacokinetic/pharmacodynamic model.
A description of PBK models, their development and
use across industrial sectors, has been reviewed previ-
ously,73,74 and recent applications of PBK modelling in
drug development specifically reported.75 In terms of per-
sonalised medicine, the models can account for genetic
predisposition, developmental stages, ethnicity, specific
disease states and drug–drug interactions. PBK models,
therefore, enable dose selection and adjustments to be made
that could not be predicted by using other modelling meth-
ods. This is of particular importance for paediatric medi-
cine. While there have been many developments in PBK
modelling, acceptance and use within the regulatory sector
has been limited. Various factors that are contributory to
this shortcoming have been suggested, such as:
– difficulties in recruiting peer reviewers with appro-
priate expertise;
– lack of confidence in PBK models for which in vivo
data are not available for evaluation;
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– problems of transferability of models across
platforms;76
– lack of dialogue between developers and regulatory
users; and
– poor consistency in model reporting.
Current collaborations between PBK modellers and risk
assessors have resulted in the publication of a harmonised
template for reporting PBK models that could assist in
decision-making. Such efforts may lead in the future to
greater acceptance and uptake of these models.77
Systems biology
Systems biology approaches explore how a biological
entity responds to stimuli. The overall response of the
system is the cumulative, integrated output of all of the
individual system components. Response may be modu-
lated by prior experience, positive or negative feedback
systems and/or compensatory mechanisms. As there are
multiple potential interactions, mathematical models are
used which comprise: (i) the relevant components of the
biological system; (ii) the individual temporal dynamic
behaviour of each component; and (iii) the interconnec-
tivity and temporal dynamic interaction between the sys-
tem components.78
Quantitative systems pharmacology (QSP) is an appli-
cation of the systems biology approach, whereby the effi-
ciency of drug discovery and development programmes
can be increased by facilitating the modelling of disease
pathology, chemical intervention and response. These
models, which can incorporate experimental data, simu-
late the outcome when a biological system is perturbed by
the presence of a xenobiotic (e.g. drug candidate) and can
provide greater mechanistic insight into the drug–target
interaction.
As with any predictive method, the models are devised
to represent a part of the system, i.e. they offer a simplified
version of the true, complete system. More complex biolo-
gical endpoints are difficult to model accurately by using
such simple models — however, useful information can be
obtained if a contributory model is developed and used
appropriately. This is an important area for 21st century
toxicology, with the prospect of Quantitative Systems
• AOPs provide a framework for organising chemical and biological informaon.
• They provide a was to organise informaon relang to the key events that lead to the perturbaon of
biological system by a xenobioc.
• They are anchored by the Molecular Iniang Event (MIE – the inial interacon between the chemical and the
biological system) and the adverse outcome (e.g. apical effect); a sequence of Key Events (KEs) link the two.
• Several MIEs may result in the same outcome and the same MIE may result in several outcomes.































Generic adverse outcome pathway (AOP)
AOP for skin sensisaon
AOPs can incorporate data from many sources e.g. informaon from in silico tools can idenfy reacve chemicals
or those possessing a relevant structural alerts; this helps to predict which compounds may elicit an MIE; in vitro
assays / biomarkers provide informaon on cellular responses; historic animal data or human data are useful for
determining apical effects.
Figure 8. Key Concepts Box: A generic adverse outcome pathway (AOP) and a specific example for skin sensitisation.
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Toxicology (QST) potentially providing a platform to inte-
grate various models for toxicodynamics and
toxicokinetics.79
The role of in silico tools in adverse
outcome pathways (AOPs)
The adverse outcome pathway (AOP) concept is an exam-
ple of a comprehensive framework that enables knowledge
acquired from in silico models, chemoinformatics, bioin-
formatics, in vitro assays, high-throughput screening,
omics technology and biological systems to be fully inte-
grated, and gaps in knowledge identified. AOPs are used to
describe the sequence of events from the initial interaction
between a chemical stressor and a biological macromole-
cule (a molecular initiating event (MIE)), through the cas-
cade of biological responses, to the resultant downstream
apical effect (the adverse outcome (AO)). The chemical
stressor must possess the relevant physico-chemical and/
or structural properties. The MIE and the AO are charac-
terised by a chain of Key Events and the relationship
between them (KERs). The relevant key concepts are
shown in Figure 8, with an outline of the generic structure
of an AOP and a specific example how the AOP concept
can be applied to skin sensitisation.
In silico tools can make significant contributions to
developing and understanding AOPs at different stages
of the process. At the initial phase, in silico tools can
provide information on chemical properties (e.g. solubi-
lity, partitioning behaviour, chemical reactivity) that can
be sourced from databases and/or predictive models.
In silico tools (such as SARs) can be used to identify
chemicals with the potential to interact with a biological
macromolecule, i.e. its potential to elicit a Molecular
Initiating Event (MIE) — which is generally considered
to be the primary step in the AOP. Knowledge of the MIE
is very powerful in predictive toxicology, and a range of
MIEs and the approaches to identifying and understanding
the MIE, at a mechanistic level, have been reported in
terms of AOP development.80 For instance, covalent inter-
actions are known to occur between xenobiotic, electro-
philic chemicals and nucleophilic groups of biological
molecules; interactions with DNA can lead to mutageni-
city or interactions with proteins of the skin or lungs can
give rise to skin sensitisation or respiratory sensitisation,
respectively.28–30 SAs, which may be grouped together as
profilers (as discussed above), can be used to identify
chemicals associated with a specific MIE, thereby provid-
ing information regarding the first step in the pathway.
The AOP concept and its applications have been
described in detail in a series of OECD Guidance Docu-
ments;81,82 continuing this effort, the OECD launched a
programme on the development of AOPs in 2013. The
Adverse Outcome Pathway-Knowledge Base (AOP-KB),
with associated wiki (https://aopwiki.org/), serves as the
repository for AOPs developed as part of the OECD AOP
Development Effort by the Extended Advisory Group on
Molecular Screening and Toxicogenomics. The wiki, cur-
rently hosted by the Society for the Advancement of
Adverse Outcome Pathways (SAAOP), lists all registered
AOPs and their current developmental status.
Effectopedia (http://www.effectopedia.org/) is an open-
knowledge platform to facilitate interdisciplinary colla-
borations to assist in AOP development. It is designed to
enable results from one experiment to be translated across
species, chemicals and levels of biological organisation,
identifying where further information is required to deter-
mine causal links between chemical interaction and biolo-
gical outcomes, offering visualisation of the elements
within an AOP. Humans and animals are usually exposed
to mixtures, rather than individual chemicals; AOPs have
also been shown to be useful in studying the effects of
mixtures in relation to chemical-induced neurotoxicity in
developmental stages.83
As the collection of AOPs develops, these will find
increasing use to support the development of QSARs. For
instance, Key Event Relationships (KERs) can inform
QSAR development;80 in turn, these KERs can be quanti-
fied, should sufficient data be available. This is the basis of
quantitative AOPs (qAOPs), which can assist in the predic-
tion of toxicological points of departure, as used in safety
assessment.84 Since AOPs are often criticised for being
presented as linear, there is growing interest in developing
AOP networks, which are more representative of the under-
lying biology. For instance, Spinu et al.85 combined various
AOPs for human neurotoxicity to develop an overall net-
work. Cytoscape (available at https://cytoscape.org/) pro-
vides a means to capture AOP networks. Analysis of such
networks helps to identify the most relevant Key Events,
and hence prioritise the development of assays and predic-
tive models. One drawback of AOPs is that, traditionally,
there has been greater focus on the steps that lead to an
adverse outcome, from a mechanistic perspective, and less
focus on the influence of the concentration–time profile of
the chemical at the target site. Greater integration of infor-
mation, such as that derived from PBK modelling, will help
to develop a more complete understanding of AOPs and the
relationship with internal dose.
Overcoming model limitations and
barriers to uptake — Future perspectives
The use of alternatives is well accepted for certain end-
points (for example, mutagenicity, irritancy or skin sensi-
tisation). However, for other, more complex endpoints
(such as repeat-dose toxicity or developmental and repro-
ductive toxicity) there are real challenges associated with
their use.86 These particularly complex endpoints are the
result of a multitude of interacting processes that are sen-
sitive to the exposure scenario (i.e. substance
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concentration, exposure duration and timing, etc.), with
these processes also varying between species and individ-
uals. While, for animal testing, extrapolations between dif-
ferent exposure scenarios or different species are fraught
with inconsistencies (that may or may not be predictable),
there is a long history of their use and comfort is derived
from keeping to the familiar uncertainties — the ‘known
unknowns’. When using combinations of NAMs to make
predictions, there is the concern of moving to unfamiliar
uncertainties and the ‘unknown unknowns’. Obtaining
ever-more detailed information from newly developing
alternatives helps to reduce these uncertainties and provide
greater confidence in the models and the predictions
derived therefrom. The rate at which new technology is
advancing and new knowledge is being gained will no
doubt alleviate concerns over time.
Twenty years ago, resources such as PubChem and
Chemspider did not exist; now data on over 100 million
chemicals can be accessed on a mobile phone. Signifi-
cantly, the past 20 years has also seen many more initia-
tives to share data, in a range of countries worldwide. For
example:
– eTOX (http://www.etoxproject.eu/) and eTRAN-
SAFE (https://etransafe.eu/) are examples of a for-
mer and a current EU-funded project. In these
initiatives, pharmaceutical companies, academia
and regulators have worked together to maximise
the use of available preclinical data for in silico
model building and evaluation.
– The EUToxRisk project (https://www.eu-toxrisk.
eu/), through multi-partner collaboration, is cur-
rently developing methods for safety assessment
of chemicals to move away from animal testing to
mechanistically-based understanding of cause and
effect of chemical toxicity by combining cell biol-
ogy, omics, systems biology and in silico
modelling.
– In 2019, a memorandum of the US EPA committed
to reducing requests for, and funding of, experiments
on mammals by 30% by 2025, with the aim of elim-
inating these entirely from 2035 (https://www.epa.
gov/research/epa-new-approach-methods-efforts-
reduce-use-animals-chemical-testing).
– A recent Blue Sky Workshop organised by the Eur-
opean Partnership for Alternative Approaches to Ani-
mal Testing (EPAA) considered the application of
NAMs, strategies for their use, challenges and oppor-
tunities. The resulting report provided recommenda-
tions for future development of the area, in terms of
both scientific research and regulatory policy.2
– The Accelerating the Pace of Chemical Risk Assess-
ment (APCRA) initiative, involving collaborations
between ECHA, US EPA and Health Canada, spe-
cifically aims to identify what is required to enable
the application and acceptance of NAMs in the reg-
ulatory sector.
– The “strategic roadmap for establishing new
approaches to evaluate the safety of chemicals and
medical products in the United States”, published
by ICCVAM (Interagency Coordinating Commit-
tee on the Validation of Alternative Methods), was
developed from the views of 16 Federal Agencies,
working groups and the public. It highlights the
disparity between the rate at which NAMs are
being developed and the impact that they currently
have in improving prediction of effects in humans.
The roadmap sets out three strategic goals for
addressing this disparity: (i) connecting end users
with developers of NAMs; (ii) fostering the use of
efficient, flexible, and robust practices to establish
confidence in new methods; and (iii) encouraging
the adoption and use of new methods and
approaches by Federal Agencies and regulated
industries.87
Initiatives like these will help to overcome barriers to the
acceptance of evidence-based NAMs in the future, and may
open the debate on how best to apply information from
developing methods such as the newer applications of arti-
ficial intelligence and machine learning techniques.
Recently, a framework has been published that provides a
consistent set of criteria by which the fitness-for-purpose of
any NAM could be evaluated. The framework comprises
three steps: (i) determining the context of use (prioritisa-
tion, hazard screening or risk assessment); (ii) ensuring
consideration of the core principles (accuracy, transpar-
ency, understanding limitations and domain of applicabil-
ity); and (iii) evaluating criteria that are relevant to the
fitness for a given purpose. The universally applicable cri-
teria were developed in collaboration with stakeholders
from industry, academia and the regulatory sector, with the
aim of encouraging the development of NAMs and increas-
ing confidence in their use in regulatory contexts.88 This
demonstrates commitment to overcoming the barriers to the
use of alternatives at the global level. Ongoing dialogue
between researchers, model developers, industry and reg-
ulators will help to overcome hesitancy, as will the tech-
nological developments that will enhance the capabilities
of alternatives.
Conclusions
The above narrative has outlined the principles and numer-
ous applications of in silico tools to predict activity, toxi-
city and ADME properties. Evidently, these are widely
used across many industries, from product development
through to safety assessment and regulatory submissions.
Tools range from databases, read-across and (Q)SARs, to
predictive software and complex machine learning
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algorithms. Some methods are simple and intuitive, while
others require much more expertise to develop and use.
Recent efforts have been directed towards developing more
transparent, mechanistically-driven models. The key to
modelling, to quote a common aphorism, is to ensure that
the model is as simple as possible, but no simpler. Looking
to the future, access to the vast amount of data being pro-
duced, the development of new technologies, and the use of
all available tools, in combination, will drive forward the
replacement of animal tests with scientifically-justified,
mechanistically-interpretable and species-relevant alterna-
tive methods.
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